Wo2010020675a1 ribociclib?

What Is Wo2010020675a1 and How Does It Relate to Ribociclib?

The patent Wo2010020675a1 is a published patent application filed by Novartis and Pfizer's joint venture, which led to the development of the CDK4/6 inhibitor ribociclib ([1] DrugPatentWatch.com). Ribociclib, marketed under the brand name Kisqali, is an oral medication used in combination with hormone therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in postmenopausal women.

How Does Ribociclib Work?

Ribociclib is a selective inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, which play a crucial role in the progression of cells from the G1 to the S phase during the cell cycle. By inhibiting these kinases, ribociclib slows down tumor growth and proliferation, ultimately improving patient outcomes ([2] DrugPatentWatch.com).

What Was the Development Timeline for Ribociclib?

In March 2018, the US FDA approved ribociclib, marking a significant milestone in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. The approval was based on data from several clinical trials, demonstrating that the combination of ribociclib and hormone therapy significantly improved progression-free survival compared to hormone therapy alone ([3] DrugPatentWatch.com).

Why Is Patent Exclusivity Important for Ribociclib?

The patent exclusivity period for ribociclib is crucial for its developers, as it provides a period of market exclusivity, allowing them to recoup their investment and generate revenue from sales of the medication. In the case of ribociclib, the patent exclusivity period is expected to last until at least 2029 ([4] DrugPatentWatch.com).

What Are the Key Competitors to Ribociclib?

Other CDK4/6 inhibitors, such as palbociclib (Ibrance) and abemaciclib (Verzenio), are also used in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. While these medications share similar mechanisms of action, their efficacy and safety profiles may differ ([5] DrugPatentWatch.com).

Sources:
[1] DrugPatentWatch.com - Ribociclib (Kisqali) Patent Summary
[2] DrugPatentWatch.com - Cyclin-dependent kinases (CDKs) 4 and 6
[3] DrugPatentWatch.com - Ribociclib (Kisqali) FDA Approval
[4] DrugPatentWatch.com - Ribociclib (Kisqali) Patent Exclusivity
[5] DrugPatentWatch.com - CDK4/6 Inhibitors: A Comparison